Perinatology.  2017 Dec;28(4):184-186. 10.14734/PN.2017.28.4.184.

Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer

• Min JW
• Kang YD

• KMID: 2409129
• DOI: http://doi.org/10.14734/PN.2017.28.4.184

Abstract

Trastuzumab is a monoclonal antibody used for the treatment of human epidermal growth factor receptor-2 positive breast cancer. There is a little information in the literature regarding the safe use of trastuzumab in pregnancy, although some reports suggest an increased risk of oligohydramnios. We present a case of woman on trastuzumab therapy for breast cancer who became pregnant and delivered healthy live infant.

Keyword

Breast cancer; Pregnancy; Trastuzumab

MeSH Terms

Breast Neoplasms*
Breast*
Epidermal Growth Factor
Female
Humans
Infant
Oligohydramnios
Pregnancy*
Trastuzumab*
Epidermal Growth Factor
Trastuzumab

Reference

1). Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. [accessed on 20 May, 2017]. Available at. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

2). National Cancer Information Center. Cancer statistics. [accessed on 20 May, 2017]. Available at. http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040102000000.

3). Park EH., Min SY., Kim Z., Yoon CS., Jung KW., Nam SJ, et al. Basic facts of breast cancer in Korea in 2014: The 10-year overall survival progress. J Breast Cancer. 2017. 20:1–11.

4). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005. 365:1687–717.

5). Bader AA., Schlembach D., Tamussino KF., Pristauz G., Petru E. Anhydram-nios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol. 2007. 8:79–81.

6). Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol. 2005. 105:642–3.

7). US Food and Drug Administration. HERCEPTIN^® (trastuzumab). [accessed on 20 May 2017]. Available at. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.

8). Peccatori FA., Azim HA Jr., Orecchia R., Hoekstra HJ., Pavlidis N., Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013. 24(Suppl 6):vi160–70.

9). Howlader N., Noone AM., Krapcho M., Neyman N., Aminou R., Waldron W, et al. SEER cancer statistics review, 1975-2008. [accessed on 20 May, 2017]. Available at. http://seer.cancer.gov/csr/1975_2008/.

10). Slamon DJ., Clark GM., Wong SG., Levin WJ., Ullrich A., McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2⁄neu oncogene. Science. 1987. 235:177–82.

11). Piccart-Gebhart MJ., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005. 353:1659–72.

12). Valero V., Forbes J., Pegram MD., Pienkowski T., Eiermann W., von Minck-witz G, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011. 29:149–56.

13). National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Breast cancer, version 2.2017. [accessed on 20 May, 2017]. Available at. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

14). Zagouri F., Sergentanis TN., Chrysikos D., Papadimitriou CA., Dimopoulos MA., Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013. 137:349–57.

15). Pant S., Landon MB., Blumenfeld M., Farrar W., Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol. 2008. 26:1567–9.

16). Azim HA Jr., Metzger-Filho O., de Azambuja E., Loibl S., Focant F., Gresko E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 2012. 133:387–91.